Life Technologies Acquires Advanced Microscopy Group

             Life Technologies Acquires Advanced Microscopy Group

- Acquisition Provides Life Technologies a Complete Set of Imaging Products
Across Range of Functionality and Price Points

- Establishes Foundation for New Product Innovation in Fluorescent and
Brightfield Imaging Devices

- Positions Life as Supplier of Integrated Imaging Systems Combining
Instrumentation and Fluorescent Labeling Reagents

PR Newswire

CARLSBAD, Calif., Nov. 5, 2012

CARLSBAD, Calif., Nov. 5, 2012 /PRNewswire/ --Life Technologies Corporation
(NASDAQ: LIFE) today announced the acquisition of Advanced Microscopy Group or
AMG, a privately held developer of imaging systems for research microscopy
incorporated as Westover Scientific, Inc. The manufacturer of the FLoid®Cell
Imaging Stationcurrently sold by Life, AMG enables Life to expand its product
line of cell imaging instrumentation, while leveraging its Molecular Probes®
portfolio of fluorescent dyes and reagents.

The acquisition also provides new product development opportunities for both
laboratory and portable imaging devices. Life Technologies' Molecular Probes®
range of fluorescent dyes and probes are broadly used in the research market
and constitute a natural complement to the EVOS® range of microscopes
manufactured by AMG.

"Our acquisition of Advanced Microscopy Group brings together two leaders in
the cell imaging field," saidPeter Dansky, president of Molecular and Cell
Biology at Life Technologies. "With AMG's demonstrated excellence in
innovative microscopy instrumentation and the Molecular Probes line of market
leading imaging reagents, we're now better able to serve our customers with a
complete portfolio of integrated solutions for cell analysis optimized for
performance and ease of use."

AMG has a portfolio of imaging instruments that spans basic to advanced
microscopy. The EVOS® range of instruments improves ease of use by eliminating
conventional eyepieces and replacing them with LCD screens. Two entry-level
microscopes, EVOS® XL and EVOS® XL-Core, address the tissue culture market for
routine monitoring of cell culture through measurements of cell density and
morphology. The instruments are brightfield and phase contrast enabled and
come with a range of magnification lens options. The EVOS®FL is a multi-color
fluorescent microscope with brightfield/phase contrast capabilities and a
range of objective options.

AMG also developed Life Technologies' FLoid®Cell Imaging Station, a platform
that offers revolutionary ease of use for fluorescent microscopy. Introduced
in late 2011, FLoid® was developed to be ideally suited for laboratories that
are new to imaging or do not require the advanced features found in more
expensive instruments. The addition of the EVOS® product line complements the
FLoid® system by maintaining simplicity in the user experience, while
providing advanced capabilities and automation that are necessary for some

"We are excited that Life Technologies places high value on our EVOS line,"
said Steve Lytle, founder and president of AMG. "Ultimately, it is our
customers who will benefit most from the breadth of the combined portfolios.
It also uniquely positions Life in the cell imaging field and will serve as
the foundation for the development of new applications and products."

The microscopy market size is estimated to be approximately $770 million. The
acquisition of AMG is expected to be neutral to Life's 2012 earnings,
accretive to 2013 earnings and accretive to the company's overall ROIC by
2015. The financial terms of the deal are not being disclosed. AMG's existing
business will remain in Bothell, Washington, and will join Life Technologies'
Flow Cytometry and Imaging business unit.

The FLoid®Cell Imaging Station is for Research Use Only, not for use in
diagnostic procedures.

About Life Technologies

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company
with customers in more than 160 countries using its innovative solutions to
solve some of today's most difficult scientific challenges. Quality and
innovation are accessible to every lab with its reliable and easy-to-use
solutions spanning the biological spectrum with more than 50,000 products for
agricultural biotechnology, translational research, molecular medicine and
diagnostics, stem cell-based therapies, forensics, food safety and animal
health. Its systems, reagents and consumables represent some of the most cited
brands in scientific research including: Ion Torrent™, Applied Biosystems®,
Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life
Technologies employs approximately 10,400 people and upholds its ongoing
commitment to innovation with more than 4,000 patents and exclusive licenses.
LIFE had sales of $3.7 billion in 2011. Visit us at our website:

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made by Life Technologies with the Securities and Exchange
Commission. Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.


Life Technologies Contact
Suzanne Clancy
858-205-4235 (mobile)

SOURCE Life Technologies Corporation

Press spacebar to pause and continue. Press esc to stop.